Compare Amgen, Inc. (AMGN) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs TKO Group Holdings Inc — how do they compare? Amgen, Inc. trades at $366.75 (market cap $196.12B), while TKO Group Holdings Inc trades at $184.36 (market cap $13.82B). The key difference: Amgen, Inc. is far larger — about 14.2× TKO Group Holdings Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | TKO | |
|---|---|---|
Market Cap | $196.12B | $13.82B |
Sector | Health | Technology |
52-Week High | $388.16 | $224.96 |
52-Week Low | $271.18 | $155.61 |
Enterprise Value | $241.41B | $18.00B |
Dividend Yield | 2.77% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
TKO trades at $184.4, down 2.01% today, with a bearish technical signal but strong analyst support. Recent earnings show a Q1 2026 beat but Q3 and Q4 2025 misses, while revenue grew to $4.74B in 2025. The company completed an $800 million share repurchase and announced a dividend, reflecting financial strength. Valuation ratios like P/E of 68.55 are elevated, but profitability margins improved.
Outlook is mixed: bullish analyst consensus with a $234 price target suggests upside, but high valuation and recent earnings volatility pose risks. Growth in live events and partnerships, like the UFC-Paramount deal, offers opportunities, yet execution and market sentiment remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
